Silicon Dioxide Chemical Properties: Reactivity, Stability and Key Reactions

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica and Hydrofluoric Acid Reaction: Equation, Mechanism and Uses
  • Keywords: 5N quartz sand
  • Published: 2026-11-20 02:03:38
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Mesoporous silica nanoparticles (MSNs) are recognized as a prime example of nanotechnology applied in the biomedical field, owing to their readily tunable structure and composition, various surface functionalization properties, and excellent biocompatibility. Over the past two decades, researchers have developed a wide range of MSNs-based nanoplatforms through careful design and controlled preparation approaches, demonstrating their adaptability to diverse biomedical application scenarios. With the continuous breakthroughs of MSNs in the fields of biosensing, disease diagnosis and treatment, tissue engineering, etc., MSNs are steadily moving from basic research to clinical trials. In this review, we supply a detailed summary of MSNs in the biomedical field, beginning with a comprehensive overview of their expansion history. We then discuss the types of MSNs-based nanostructured architectures, along with the classification of MSNs-based nanocomposites according to the elements existed in diverse inorganic functional factors. Subsequently, we summarize the primary purposes of surface-functionalized modifications of MSNs. In the following, we examine the biomedical applications of MSNs, and highlight the MSNs-based targeted therapeutic modalities currently developed. Given the importance of clinical translation, we also summarize the progress of MSNs in clinical trials. Lastly, we take a perspective on the future direction and remaining difficulties of MSNs in the biomedical field.

Silica vs Silicone: Key Differences in Structure, Properties and Uses

Silica Matting Agent: How It Works, Key Specs and How to Choose the Right Grade
Cai, D. et al. Chitosan-capped enzyme-responsive hollow mesoporous silica nanoplatforms for colon-specific drug delivery. Nanoscale Res. Lett. 15, 123 (2020). Article CAS PubMed Central PubMed Google Scholar
Silica Testing Methods: How to Test Purity, Particle Size, BET and Moisture
Ultra Pure Silica: What Purity Level You Need and Which Industries Use It
Silica Market Trends 2026: Demand Drivers, Technologies and Regional Outlook
Cheng, X., Tu, D., Zheng, W. & Chen, X. Energy transfer designing in lanthanide-doped upconversion nanoparticles. Chem. Commun. 56, 15118-15132 (2020). Piece CAS Google Scholar

Acidic Silica Sol: Properties, Stability and Applications

What is silica (SiO₂)?

spherical silica for semiconductor packaging Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.

What is the difference between fumed silica and precipitated silica?

how to disperse fumed silica Aghayan, M. et al. The expansion of a novel copper-loaded mesoporous silica nanoparticle as a peroxidase mimetic for colorimetric biosensing and its application in H2O2 and GSH assay. Anal. Sci. 39, 1-11 (2023). Article Google Scholar

What drives silica raw material prices?

Cite this article: Silica Raw Materials News. "Silica SDS: Key Hazards, Handling and Storage Information Explained ." Published 2026-11-20 02:03:38. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.